Premium
Targeting siRNA in colorectal cancer therapy: Nanotechnology comes into view
Author(s) -
Aghamiri Shahin,
Jafarpour Ali,
Malekshahi Ziba Veisi,
Mahmoudi Gomari Mohammad,
Negahdari Babak
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.28281
Subject(s) - colorectal cancer , small interfering rna , medicine , multiple drug resistance , cancer , chemotherapy , drug resistance , cancer therapy , targeted therapy , cancer research , bioinformatics , biology , gene , rna , biochemistry , microbiology and biotechnology
Colorectal cancer (CRC) is known as one of the most important causes of death and mortality worldwide. Although several efforts have been made for finding new therapies, no achievements have been made in this area. Multidrug resistance (MDR) mechanisms are one of the key factors that could lead to the failure of chemotherapy. Moreover, it has been shown that various chemotherapy drugs are associated with several side effects. Hence, it seems that finding new drugs or new therapeutic platforms is required. Among different therapeutic approaches, utilization of nanoparticles (NPs) for targeting a variety of molecules such as siRNAs are associated with good results for the treatment of CRC. Targeting siRNA‐mediated NPs could turn off the effects of oncogenes and MDR‐related genes. In the current study, we summarized various siRNAs targeted by NPs which could be used for the treatment of CRC. Moreover, we highlighted other routes such as liposome for targeting siRNAs in CRC therapy.